9月19日欧林生物大宗交易一览 证券时报·数据宝统计显示，欧林生物今日收盘价为26.80元，下跌1.43%，日换手率为1.54%，成交额为 1.71亿元，全天主力资金净流入284.67万元，近5日该股累计下跌2.37%，近5日资金合计净流入7972.38 万元。 两融数据显示，该股最新融资余额为3.59亿元，近5日增加6384.40万元，增幅为21.66%。 据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日。注册资本40593.36万人民 币。（数据宝） 欧林生物9月19日大宗交易平台共发生2笔成交，合计成交量28.80万股，成交金额656.06万元。成交价格 均为22.78元，相对今日收盘价折价15.00%。 进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为2618.11万元。 | 成交量 | 成交金额 | 成交价 格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | | 溢价（%） | | | | 股） | | （元） | | | | | 20.00 | ...

关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688319 证券简称：欧林生物 公告编号：2025-047 成都欧林生物科技股份有限公司 二、补助的类型及对上市公司的影响 根据《企业会计准则第 16 号——政府补助》等有关规定，公司上述获得的政 府补助属于与收益相关的政府补助。由于相关政府补助项目存在验收条件，需在 满足相关条件后才能计入当期损益，因此尚无法确定上述政府补助对公司本年度 及之后年度利润产生的影响。上述政府补助未经审计，具体的会计处理以及对公 司 2025 年度以及之后年度损益的影响最终以会计师年度审计确认后的结果为准。 敬请投资者注意投资风险。 特此公告。 成都欧林生物科技股份有限公司董事会 2025 年 9 月 20 日 一、获得补助的基本情况 近期，成都欧林生物科技股份有限公司(以下简称"公司")"重组多重耐药 金黄色葡萄球菌疫苗研制与产业化"项目入选四川省2025年第二批省级科技计划， 公司于 2025 年 9 月 19 日收到政府补助款项共计人民币 464 万元， ...

Group 1 - The core point of the article is that Olin Bio (SH 688319) has received a government subsidy of 4.64 million RMB for its project on the development and industrialization of a vaccine for multi-drug resistant Staphylococcus aureus, which is part of the Sichuan provincial science and technology plan for 2025 [1] - The company reported that its revenue composition for the year 2024 will be 99.53% from the pharmaceutical manufacturing industry and 0.47% from other businesses [1] - As of the latest update, Olin Bio has a market capitalization of 10.9 billion RMB [2]

格隆汇9月19日丨欧林生物(688319.SH)公布，公司"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项 目入选四川省2025年第二批省级科技计划，公司于2025年9月19日收到政府补助款项共计人民币464万 元，其中324.8万元为公司所获政府补助；其余139.2万元为项目合作单位所获政府补助。本次收到的政 府补助将全部计入公司专项应付款科目，并按照相关规定根据项目后续完成及验收情况进行相应会计处 理。公司所获政府补助324.8万元均为与收益相关的政府补助。 ...

格隆汇9月19日丨欧林生物(688319.SH)公布，公司"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项 目入选四川省2025年第二批省级科技计划，公司于2025年9月19日收到政府补助款项共计人民币464万 元，其中324.8万元为公司所获政府补助；其余139.2万元为项目合作单位所获政府补助。本次收到的政 府补助将全部计入公司专项应付款科目，并按照相关规定根据项目后续完成及验收情况进行相应会计处 理。公司所获政府补助324.8万元均为与收益相关的政府补助。 ...

进一步统计，近3个月内该股累计发生5笔大宗交易，合计成交金额为1962.05万元。 欧林生物9月18日大宗交易平台出现一笔成交，成交量8.70万股，成交金额201.06万元，大宗交易成交价 为23.11元，相对今日收盘价折价15.01%。该笔交易的买方营业部为中信建投证券股份有限公司北京望 京证券营业部，卖方营业部为广发证券股份有限公司成都麓山大道证券营业部。 9月18日欧林生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 8.70 | 201.06 | 23.11 | -15.01 | 中信建投证券股份有限公 | 广发证券股份有限公司成 | | | | | | 司北京望京证券营业部 | 都麓山大道证券营业部 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，欧林生物今日收盘价为27.19元，下跌3.1 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2025-09-18 | 欧林生物 | 688319 | 23.11 201.06 | 8.7 | 中信建投证券股份 | 广发证券股份有限 | | | | | | | 有限公司北京望京 | 公司成都麓山大道 | | | | | | | 1 7 4 2 2 1 . 40 | ST 44 22 . 1 . 40 | 9月18日，欧林生物大宗交易成交8.7万股，成交额201.06万元，占当日总成交额的0.57%，成交价23.11元，较市场收盘价27.19元折价15.01%。 ...

Group 1 - The core viewpoint of the news is the performance and financial details of Olin Bio, which saw a stock price increase of 5.3% to 28.40 CNY per share, with a total market capitalization of 11.529 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with the majority of its revenue coming from the adsorbed tetanus vaccine at 90.99% [1] - The company also generates revenue from other vaccines, including A group and C group meningococcal polysaccharide conjugate vaccine (4.49%), b-type Haemophilus influenzae type b conjugate vaccine (3.99%), and others [1] Group 2 - From the perspective of fund holdings, Olin Bio is a significant investment for the Fuyong Fund, with its Fuyong Medical Health Mixed Fund A (015655) holding 17,200 shares, representing 2.06% of the fund's net value [2] - The fund has seen a year-to-date return of 14.22% and a one-year return of 10.55%, although it has experienced a loss of 20.8% since its inception [2]

Core Insights - The innovation drug industry in China is experiencing significant advancements in product research and development, with companies actively discussing their progress and strategies during the recent performance briefing session [1][2][3]. Group 1: Product Innovation and R&D Progress - Companies like Fudan Zhangjiang and Olin Bio are making notable advancements in their product pipelines, focusing on photodynamic therapy and vaccines for "super bacteria" [1][2]. - Fudan Zhangjiang is developing several drugs targeting conditions such as severe acne and bladder cancer, with ongoing clinical studies [2]. - Olin Bio is researching multiple vaccines for "super bacteria," aiming to initiate clinical trials for flu vaccines by mid-2025 [2]. Group 2: Business Expansion and Market Strategy - Companies are planning to expand their production capacity to support product commercialization, with Baiyao Tai focusing on launching several products that have completed Phase III clinical trials [3][4]. - Shian Bio is set to contribute significant revenue from its various vaccine products, including those for swine fever and other diseases [4]. Group 3: Internationalization and Market Entry - The trend of "going global" is a major focus for the domestic biopharmaceutical industry, with companies exploring diverse international pathways [5]. - Yuantong Bio is awaiting FDA approval for its naloxone nasal spray, marking a step towards international market entry [5]. - Aidi Pharmaceutical has received regulatory approval for its HIV treatment in Zanzibar, highlighting its international expansion efforts [6]. - Companies like Ailis and Haichuang Pharmaceutical are actively pursuing overseas partnerships and clinical trials to enhance their global presence [6][7].

Core Viewpoint - The company, Chengdu Olin Biological Technology Co., Ltd., is focusing on enhancing its market position through medical education and product promotion while advancing its vaccine research and clinical trials for Staphylococcus aureus and influenza vaccines [1][2]. Financial Performance - In the first half of 2025, the company achieved a revenue of 306 million yuan, representing a year-on-year growth of 35.17% [1]. - The net profit attributable to shareholders was 13.2 million yuan, with a net profit of 7.72 million yuan after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year [1]. R&D Pipeline - The company is focusing on two strategic directions: "super bacteria" vaccines and "adult vaccines," continuously enriching its pipeline and enhancing innovation capabilities [2]. - The company is researching four "super bacteria" vaccines, including recombinant Staphylococcus aureus vaccine, oral recombinant Helicobacter pylori vaccine, recombinant Pseudomonas aeruginosa vaccine, and recombinant Acinetobacter baumannii protein vaccine, all classified as global Class 1 new drugs [2]. Clinical Trials - The recombinant Staphylococcus aureus vaccine has completed Phase I and II clinical trials, with Phase III trials currently ongoing and leading globally [2]. - The vaccine aims to prevent Staphylococcus aureus infections post-surgery, with no similar products available globally, indicating a broad application potential in hospital infection prevention [3]. - The company’s Helicobacter pylori vaccine received Phase I clinical trial approval in Australia in 2024, and further optimization of the oral formulation is underway for future domestic clinical trial applications [3]. Technological Advancements - The company is expanding its technological platforms and has made significant progress in the field of viral vaccines, having initiated Phase I clinical trials for trivalent and quadrivalent influenza virus split vaccines in the first half of 2025 [3].